statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Gossamer Bio assumed with an Outperform at Wedbush

Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) CEO Faheem Hasnain sold 23,172 shares of the company's stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an...

Gossamer Bio, Inc. (NASDAQ:GOSS) CEO Sells $26,879.52 in Stock

Gossamer Bio (NASDAQ:GOSS  Get Free Report)s stock had its overweight rating reiterated by Piper Sandler in a research note issued on Wednesday, Benzinga reports. They...

Gossamer Bio (NASDAQ:GOSS) Stock Rating Reaffirmed by Piper Sandler

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Gossamer Bio, Inc. (NASDAQ:GOSS  Get Free Report) has received an average recommendation of Moderate Buy from the five ratings firms that are covering the company...

Gossamer Bio, Inc. (NASDAQ:GOSS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Gossamer Bio (NASDAQ:GOSS  Get Free Report) had its price target dropped by stock analysts at The Goldman Sachs Group from $9.00 to $8.00 in a report issued on Wednesday, Benzinga reports. The...

Gossamer Bio (NASDAQ:GOSS) Price Target Lowered to $8.00 at The Goldman Sachs Group

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS  Get Free Report) have been given an average rating of Hold by the six research firms that are presently covering the stock, Marketbeat...

Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) PT at $4.75

Gossamer Bio (NASDAQ:GOSS  Free Report) had its target price upped by HC Wainwright from $5.00 to $10.00 in a report published on Monday, Benzinga reports. They currently have a buy rating on...

HC Wainwright Raises Gossamer Bio (NASDAQ:GOSS) Price Target to $10.00

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Volume	4.33M
52-Wk High	$1.88
52-Wk Low	$0.4525

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.19	--	--	N/A
Q4'23	-$0.21	-$0.21	-0.80%	MISSED
Q3'23	-$0.26	-$0.21	18.11%	BEAT
Q2'23	-$0.49	-$0.45	8.02%	BEAT
Q1'23	-$0.53	-$0.52	1.89%	BEAT

GOSS Gossamer Bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals